Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have ... Read More
EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial
EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the Phase 2 PAVIA clinical trial for DURAVYU ... Read More
ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene therapy for diabetic retinopathy (DR) treatment. This ... Read More
OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial
OcuTerra Therapeutics, a clinical-stage ophthalmology company, announced the successful full enrollment in its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial. The trial ... Read More
FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment
Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for its lucentis (ranibizumab injection), making it ... Read More